Calliditas Therapeutics AB (OSTO:CALTX)
kr 204.8 0.2 (0.1%) Market Cap: 10.99 Bil Enterprise Value: 11.20 Bil PE Ratio: 0 PB Ratio: 91.47 GF Score: 36/100

Q4 2020 Calliditas Therapeutics AB Earnings Call Transcript

Feb 18, 2021 / 01:30PM GMT
Release Date Price: kr128.6 (-3.02%)
Operator

Ladies and gentlemen welcome to the Calliditas Therapeutics Q4 2020. Today, I'm pleased to present CEO, Renee Lucander; and CFO, Fredrik Johansson.

(Operator Instructions)

Renee, please begin.

Renee Aguiar;Lucander;publ;CEO
Calliditas Therapeutics AB

()-

Thank you very much, and welcome to Calliditas Q4 2020 report. And if you -- as you're aware, obviously, there is a disclaimer. And so during today's call, we'll be making certain forward-looking statements may include statements among other things about the timing progress of results. Our ongoing Phase III clinical trials for Nefecon, development plan for setanaxib or any other future product candidates, timing, scope, likelihood, domestic, and/or foreign regulatory filings and approvals. Those forward-looking statements are based on current information assumption and expectations, are subject to change. And involve risks and uncertainties that may cause the actual results to differ materially from those contained in the forward-looking

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot